At-Risk Patient Populations

Iron deficiency (ID) and iron deficiency anemia (IDA) rarely occur in isolation.49,50,51

Across a range of clinical contexts, inadequate iron levels can contribute to worsening symptoms and increased risk of mortality.

The ACCRUFeR® (ferric maltol) impact

These profiles highlight patient populations with an increased risk for ID and IDA.

Woman smiling in front of a red and white background

Patients with Inflammatory Conditions

Chronic inflammation disrupts iron absorption and ID worsens inflammation.51,49

ACCRUFeR’s unique design demonstrated absorption and tolerability in patients with ID/IDA and inflammatory conditions.2

Learn about ID and inflammation
Black woman smiling in front of a purple background

Female Patients

For women, ongoing iron loss and intolerance of ferrous salts can be barriers to maintaining healthy iron levels.18,32

ACCRUFeR demonstrated rapid results and significant Hb improvement for adults with ID/IDA.2

Learn about ID in women
Young teen girl smiling in front of a yellow and white background

Pediatric Patients

Without timely intervention in adolescents, some effects of ID/IDA may not be reversible.8,47

ACCRUFeR is the only FDA-approved branded oral iron treatment for children 10 years of age and older.2,60

Learn about ID in pediatric patients

Downsides of Oral Iron Salts

Learn why iron supplements can make your patients feel worse instead of better.

About ACCRUFeR

See how ACCRUFeR's MALTOL SHIELDTM helps minimize the risk of gastrointestinal side effects.2-4

References:
2. ACCRUFeR® full prescribing information. Shield Therapeutics, 2025
3. Stallmach A, Büning C. Ferric maltol (ST10): a novel oral iron supplement for the treatment of iron deficiency anemia in inflammatory bowel disease. Expert Opin Pharmacother. 2015;16(18):2859-2867. doi:10.1517/14656566.2015.1096929
4. European Medicines Agency. Accessed March 17, 2021. https://www.ema.europa.eu/en/documents/variation-report/feraccru-h-c-2733-ii-0010-epar-assessment-report-variation_en.pdf. 
8. Iron-deficiency anemia. National Heart Lung and Blood Institute. Accessed October 30, 2023. https://www.nhlbi.nih.gov/health/anemia/iron-deficiency-anemia
18. Friedman AJ, Chen Z, Ford P, et al. Iron deficiency anemia in women across life span. J Womens Health (Larchmt).2012;21(12):1282-128
26. Anaemia in women and children. World Health Organization. 2021. Accessed October 30, 2023. https://www.who.int/data/gho/data/themes/topics/anaemia_in_women_and_children
32. Cancelo-Hidalgo MJ, Castelo-Branco C, Palacios S, et al. Tolerability of different oral iron supplements: A systematic review. Curr Med Res Opin. 2013;29(4):291-303. doi:10.1185/03007995.2012.761599.
47. Theola, J., & Andriastuti, M. (2025). Neurodevelopmental impairments as long-term effects of iron deficiency in early childhood: A systematic review. Balkan Medical Journal. https://doi.org/10.4274/balkanmedj.galenos.2025.2024-11-24
49. Cappellini MD, Comin-Colet J, de Francisco A, et al. IRON CORE Group. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. Am J Hematol. 2017 Oct;92(10):1068- 1078. doi: 10.1002/ajh.24820. Epub 2017 Jul 7. PMID: 28612425; PMCID: PMC5599965. 
50. Kempf T, Geller W, Fuge J, et al. Oral ferric maltol improves iron deficiency anaemia in patients with chronic heart failure. Eur J Heart Fail 2025. https://doi.org/10.1002/ ejhf.3789
51. Olsson K, Fuge J, Brod T, et al. Oral iron supplementation with ferric maltol in patients with pulmonary hypertension. Eur Respir J. Nov 2020. 12;56(5): 2000616.
60. Data on File. Shield Therapeutics Inc. 2025